These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 6210237

  • 1. Thyroid stimulating immunoglobulins in patients in long-term remission after Graves' disease.
    Bliddal H, Bech K, Kirkegaard C.
    Horm Metab Res; 1984 Nov; 16(11):602-5. PubMed ID: 6210237
    [Abstract] [Full Text] [Related]

  • 2. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A.
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [Abstract] [Full Text] [Related]

  • 3. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK, Plicht M, Lax H, Hirche H, Quadbeck B, Mann K, Steuhl KP, Esser J, Morgenthaler NG.
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [Abstract] [Full Text] [Related]

  • 4. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D, Massart C.
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [Abstract] [Full Text] [Related]

  • 5. [Long-term evolution of immunologic and thyroid function in Graves disease according different therapeutic options].
    Campos Pastor MM, Fernández Soto ML, Escobar-Jiménez F, Barredo Acedo F, Ruiz de Almodóvar M.
    Med Clin (Barc); 1994 Apr 02; 102(12):446-50. PubMed ID: 7516033
    [Abstract] [Full Text] [Related]

  • 6. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M, Minich WB, Willenberg HS, Papewalis C, Seissler J, Feldkamp J, Bergmann A, Scherbaum WA, Morgenthaler NG.
    Horm Metab Res; 2005 Dec 02; 37(12):741-4. PubMed ID: 16372227
    [Abstract] [Full Text] [Related]

  • 7. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K.
    J Endocrinol Invest; 1997 Sep 02; 20(8):452-61. PubMed ID: 9364248
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H, Amino N, Aozasa M, Mori M, Tanizawa O, Miyai K.
    J Clin Endocrinol Metab; 1987 Aug 02; 65(2):324-30. PubMed ID: 2885336
    [Abstract] [Full Text] [Related]

  • 11. [Clinical studies on abnormal thyroid stimulators in patients with Graves' disease. II. Clinical significance of measuring TSAb and TBII in patients with euthyroid Graves' disease and patients with hyperthyroid Graves' disease during antithyroid drug treatment].
    Uno C, Nishikawa M.
    Nihon Naibunpi Gakkai Zasshi; 1988 Mar 20; 64(3):206-15. PubMed ID: 2456230
    [Abstract] [Full Text] [Related]

  • 12. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N, Kamijo K, Sato Y, Yoshimura H, Nagata A, Ochi Y.
    Clin Exp Pharmacol Physiol; 2004 Mar 20; 31(5-6):314-9. PubMed ID: 15191404
    [Abstract] [Full Text] [Related]

  • 13. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP, Ratanachaiyavong S, Middleton GW, Love W, John R, Owen GM, Darke C, Lazarus JH, Hall R, McGregor AM.
    Q J Med; 1986 Apr 20; 59(228):409-19. PubMed ID: 2875484
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Failure of anti-TSH receptor antibodies (TRAb) to predict the outcome of the course of Graves' disease following withdrawal of antithyroid drug.
    Shoda Y, Akiyama H, Yamaguchi T, Inukai T, Kobayashi I, Kondo Y, Kobayashi S.
    Exp Clin Endocrinol; 1991 Mar 20; 97(1):113-6. PubMed ID: 1677893
    [Abstract] [Full Text] [Related]

  • 16. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
    Shibayama K, Ohyama Y, Yokota Y, Ohtsu S, Takubo N, Matsuura N.
    Endocr J; 2005 Oct 20; 52(5):505-10. PubMed ID: 16284425
    [Abstract] [Full Text] [Related]

  • 17. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H, Hirota Y, Kasagi K, Matsubayashi S, Kuma K, Iida Y, Konishi J, Okimura MC, Walter RM, Kumagai LF.
    J Clin Endocrinol Metab; 1987 Apr 20; 64(4):718-22. PubMed ID: 2434520
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Paired determination of thyroid-stimulating and TSH-binding inhibitory activities in patients with Graves' disease during antithyroid drug treatment.
    Kasagi K, Iida Y, Konishi J, Misaki T, Arai K, Endo K, Torizuka K, Kuma K.
    Acta Endocrinol (Copenh); 1986 Apr 20; 111(4):474-80. PubMed ID: 2422860
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of TSH-receptor antibodies as prognostic markers after cessation of antithyroid drug treatment in patients with Graves' disease.
    Kasagi K, Iida Y, Hatabu H, Tokuda Y, Arai K, Endo K, Konishi J.
    Acta Endocrinol (Copenh); 1988 Feb 20; 117(2):173-80. PubMed ID: 2454576
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.